Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefixime versus cefixime + clindamycin for acute and chronic sinusitis
IRCT20201112049371N1Phase 3Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of cefixime and clindamycin in acute rhinosinusitis (ARS) and rhinosinusitis (4 arms), sponsored by Ahvaz Jundishapur University of Medical Sciences. Primary endpoint: Treatment of acute and chronic sinusitis. Started Jun 2020; status: completed.
02
Drugs
cefiximeclindamycin
03
Conditions
acute rhinosinusitis (ARS)rhinosinusitis
Beyond the preview
Go deeper on IRCT20201112049371N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201112049371N1.